A Beacon Of Hope : The Treatment That Could Change Everything For Liver Cancer Patients

Add as a preferred source on Google

Liver cancer, specifically hepatocellular carcinoma (HCC), is one of the most common and deadliest types of cancer worldwide. In India, the lack of awareness means many people don't realise they have it until it's too late. But recent medical advancements are bringing new hope, especially for patients who can't have surgery.

Photo Credit: Pexels

Immunotherapy, a groundbreaking treatment, is offering a fresh chance at life.

The Promise Of Immunotherapy

Immunotherapy is a treatment that uses the body's own immune system to fight cancer. Recent findings from two pivotal phase III clinical trials published in The Lancet have heralded a new chapter in HCC treatment, showing that immunotherapy can slow down the growth of liver cancer. This treatment can be used alone or combined with other methods, giving doctors more tools to help patients.

The Importance Of Early Detection

While these medical breakthroughs are promising, catching liver cancer early is still critical. Regular check-ups are essential, especially for those at high risk, like people with liver cirrhosis or chronic hepatitis B and C. Early detection can make a big difference, allowing for more effective treatments and better chances of survival.

The High Cost Of Hope

One of the biggest challenges with immunotherapy is its cost. In India, a single vial can cost over one lakh rupees, making it out of reach for many patients. This high price is a major barrier, and there's a pressing need to find ways to make this treatment more affordable so more people can benefit from it.

Traditional Treatments : What Is TACE?

Before immunotherapy, a common treatment for liver cancer was transarterial chemo-embolization (TACE). This method involves delivering chemotherapy directly to the liver to block the blood supply to the tumour. While TACE can help slow down the cancer, its effects don't last long, and doctors are always looking for better solutions.

Combining New And Old : Immunotherapy With TACE

Recent clinical trials, like EMERALD-1 and LEAP-012, have tested combining immunotherapy with TACE. The results are encouraging. For example, the EMERALD-1 trial showed that combining immunotherapy drugs durvalumab and bevacizumab with TACE delayed cancer progression by 6.8 months compared to TACE alone. Similarly, the LEAP-012 trial found that using pembrolizumab and lenvatinib with TACE improved progression-free survival by 4.6 months. These results show that combining these treatments could offer new hope for patients.

Challenges Still Remain

While the combination of immunotherapy and TACE looks promising, it's not without risks. For patients with a history of hepatitis, there's a chance that their healthy liver cells could also be affected by the treatment. This is a challenge that doctors will need to carefully manage as these new treatments become more widely used.

Photo Credit: Image is AI-generated

Immunotherapy offers new hope for those battling liver cancer, but the high cost remains a significant hurdle. As research continues and efforts are made to reduce costs, there's potential for this treatment to transform liver cancer care in India. With more accessible treatments, patients can look forward to better outcomes and a brighter future in their fight against this deadly disease.

Disclaimer: The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified healthcare provider with any questions you may have regarding a medical condition.